Generalized Myasthenia Gravis (GMG) Managements Market
Global Industry Analysis 2017-2022 and Opportunity Assessment 2023-2033
A recent market study published by FMI on Generalized Myasthenia Gravis (GMG) Managements offers a global industry analysis for 2017-2022 and opportunity assessment for 2023-2033. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.
Market Segmentation
By Drug Types:
- Monoclonal Antibodies
- FcRn Inhibitors
- Corticosteroid
- Cholinesterase Inhibitors
- Pharmacotherapy
- Therapeutic Plasma Exchange
- Hospitals
- Specialty Clinics
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Executive Summary
The executive summary of the Generalized Myasthenia Gravis (GMG) Managements Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Vehicle Radar Test System.
Chapter 01 - Market Overview
Readers can find the detailed segmentation and definition of the Generalized Myasthenia Gravis (GMG) Managements Market in this chapter, which will help to understand basic information about Vehicle Radar Test System. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Generalized Myasthenia Gravis (GMG) Managements Market report.
Chapter 02 - Market Background
This chapter includes detailed analysis of the By Drug Types processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.
Chapter 03 - Global Generalized Myasthenia Gravis (GMG) Managements Market Demand Analysis 2017-2022 and Forecast, 2023-2033
The chapter include historical market value (XX) analysis (2017-2022) and current and future market value (US$ 1.32 Billion) and volume (7.6%) projections (2023-2033). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.
Chapter 04 - Global Generalized Myasthenia Gravis (GMG) Managements Market - Pricing Analysis
Based on By Drug Types, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.
Chapter 05 - Global Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033, By Drug Types
Based on By Drug Types, Generalized Myasthenia Gravis (GMG) Managements Market is segmented into Monoclonal Antibodies, FcRn Inhibitors, Corticosteroid, Cholinesterase Inhibitors, Pharmacotherapy, Therapeutic Plasma Exchange. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Drug Types.
Chapter 06 - Global Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033, By End Users
Based on By End Users, Generalized Myasthenia Gravis (GMG) Managements Market is segmented into Hospitals, Specialty Clinics, Others. This section also offers market attractiveness analysis based on By End Users. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By End Users.
Chapter 07 - Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033, By Region
Based on By Region, Generalized Myasthenia Gravis (GMG) Managements Market is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and MEA. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.
Chapter 08 - North America Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of the Vehicle Radar Test System in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.
Chapter 09 - Latin America Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Generalized Myasthenia Gravis (GMG) Managements Market in the Latin America region.
Chapter 10 - Europe Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Generalized Myasthenia Gravis (GMG) Managements Market in the regional market.
Chapter 11 - East Asia Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Generalized Myasthenia Gravis (GMG) Managements Market in the regional market.
Chapter 12 - South Asia Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Generalized Myasthenia Gravis (GMG) Managements Market in the regional market.
Chapter 13 - Middle East and Africa Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Generalized Myasthenia Gravis (GMG) Managements Market in the regional market.
Chapter 14 - Key Countries Generalized Myasthenia Gravis (GMG) Managements Market Analysis 2017-2022 and Forecast 2023-2033
This chapter offers insights into how the Generalized Myasthenia Gravis (GMG) Managements Market is expected to grow in major countries globally.
Chapter 15 - Market Structure Analysis- Global Assessment
This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.
Chapter 16 - Competition Deep Dive (Tentative List)
This chapter includes company overview, By Drug Types portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Alexion Pharmaceuticals, Argenx, UCB Biopharma, Horizon Therapeutics, Halozyme Therapeutics, Hoffmann-La Roche AG, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics.
Chapter 17 - Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Vehicle Radar Test System report.
Chapter 18 - Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Generalized Myasthenia Gravis (GMG) Managements Market.
- 1. Executive Summary | Generalized Myasthenia Gravis (GMG) Management Market
- 1.1. Global Market Outlook
- 1.2. Demand-side Trends
- 1.3. Supply-side Trends
- 1.4. Technology Roadmap Analysis
- 1.5. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 3. Market Background
- 3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
- 3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
- 3.3. Opportunity Map Analysis
- 3.4. Investment Feasibility Matrix
- 3.5. PESTLE and Porter’s Analysis
- 3.6. Regulatory Landscape
- 3.6.1. By Key Regions
- 3.6.2. By Key Countries
- 3.7. Regional Parent Market Outlook
- 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
- 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
- 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis
- 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Treatment
- 5.1. Introduction / Key Findings
- 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
- 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
- 5.3.1. Drug Types
- 5.3.1.1. Monoclonal Antibodies
- 5.3.1.2. FcRn Inhibitors
- 5.3.1.3. Corticosteroids
- 5.3.1.4. Cholinesterase Inhibitors
- 5.3.2. Pharmacotherapy
- 5.3.3. Therapeutic Plasma Exchange
- 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
- 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
- 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By End Users
- 6.1. Introduction / Key Findings
- 6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
- 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
- 6.3.1. Hospitals
- 6.3.2. Specialty Clinics
- 6.3.3. Others
- 6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
- 6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
- 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Region
- 7.1. Introduction
- 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
- 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
- 7.3.1. North America
- 7.3.2. Latin America
- 7.3.3. Europe
- 7.3.4. Asia Pacific
- 7.3.5. Middle East and Africa (MEA)
- 7.4. Market Attractiveness Analysis By Region
- 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
- 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 8.2.1. By Country
- 8.2.1.1. United States of America
- 8.2.1.2. Canada
- 8.2.2. By Treatment
- 8.2.3. By End Users
- 8.3. Market Attractiveness Analysis
- 8.3.1. By Country
- 8.3.2. By Treatment
- 8.3.3. By End Users
- 8.4. Key Takeaways
- 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
- 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 9.2.1. By Country
- 9.2.1.1. Brazil
- 9.2.1.2. Mexico
- 9.2.1.3. Rest of Latin America
- 9.2.2. By Treatment
- 9.2.3. By End Users
- 9.3. Market Attractiveness Analysis
- 9.3.1. By Country
- 9.3.2. By Treatment
- 9.3.3. By End Users
- 9.4. Key Takeaways
- 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
- 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 10.2.1. By Country
- 10.2.1.1. Germany
- 10.2.1.2. United Kingdom
- 10.2.1.3. France
- 10.2.1.4. Spain
- 10.2.1.5. Italy
- 10.2.1.6. Rest of Europe
- 10.2.2. By Treatment
- 10.2.3. By End Users
- 10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Treatment
- 10.3.3. By End Users
- 10.4. Key Takeaways
- 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
- 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 11.2.1. By Country
- 11.2.1.1. China
- 11.2.1.2. Japan
- 11.2.1.3. South Korea
- 11.2.1.4. Singapore
- 11.2.1.5. Thailand
- 11.2.1.6. Indonesia
- 11.2.1.7. Australia
- 11.2.1.8. New Zealand
- 11.2.1.9. Rest of Asia Pacific
- 11.2.2. By Treatment
- 11.2.3. By End Users
- 11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Treatment
- 11.3.3. By End Users
- 11.4. Key Takeaways
- 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country
- 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 12.2.1. By Country
- 12.2.1.1. GCC Countries
- 12.2.1.2. South Africa
- 12.2.1.3. Israel
- 12.2.1.4. Rest of MEA
- 12.2.2. By Treatment
- 12.2.3. By End Users
- 12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Treatment
- 12.3.3. By End Users
- 12.4. Key Takeaways
- 13. Key Countries Market Analysis
- 13.1. United States of America
- 13.1.1. Pricing Analysis
- 13.1.2. Market Share Analysis, 2022
- 13.1.2.1. By Treatment
- 13.1.2.2. By End Users
- 13.2. Canada
- 13.2.1. Pricing Analysis
- 13.2.2. Market Share Analysis, 2022
- 13.2.2.1. By Treatment
- 13.2.2.2. By End Users
- 13.3. Brazil
- 13.3.1. Pricing Analysis
- 13.3.2. Market Share Analysis, 2022
- 13.3.2.1. By Treatment
- 13.3.2.2. By End Users
- 13.4. Mexico
- 13.4.1. Pricing Analysis
- 13.4.2. Market Share Analysis, 2022
- 13.4.2.1. By Treatment
- 13.4.2.2. By End Users
- 13.5. Germany
- 13.5.1. Pricing Analysis
- 13.5.2. Market Share Analysis, 2022
- 13.5.2.1. By Treatment
- 13.5.2.2. By End Users
- 13.6. United Kingdom
- 13.6.1. Pricing Analysis
- 13.6.2. Market Share Analysis, 2022
- 13.6.2.1. By Treatment
- 13.6.2.2. By End Users
- 13.7. France
- 13.7.1. Pricing Analysis
- 13.7.2. Market Share Analysis, 2022
- 13.7.2.1. By Treatment
- 13.7.2.2. By End Users
- 13.8. Spain
- 13.8.1. Pricing Analysis
- 13.8.2. Market Share Analysis, 2022
- 13.8.2.1. By Treatment
- 13.8.2.2. By End Users
- 13.9. Italy
- 13.9.1. Pricing Analysis
- 13.9.2. Market Share Analysis, 2022
- 13.9.2.1. By Treatment
- 13.9.2.2. By End Users
- 13.10. China
- 13.10.1. Pricing Analysis
- 13.10.2. Market Share Analysis, 2022
- 13.10.2.1. By Treatment
- 13.10.2.2. By End Users
- 13.11. Japan
- 13.11.1. Pricing Analysis
- 13.11.2. Market Share Analysis, 2022
- 13.11.2.1. By Treatment
- 13.11.2.2. By End Users
- 13.12. South Korea
- 13.12.1. Pricing Analysis
- 13.12.2. Market Share Analysis, 2022
- 13.12.2.1. By Treatment
- 13.12.2.2. By End Users
- 13.13. Singapore
- 13.13.1. Pricing Analysis
- 13.13.2. Market Share Analysis, 2022
- 13.13.2.1. By Treatment
- 13.13.2.2. By End Users
- 13.14. Thailand
- 13.14.1. Pricing Analysis
- 13.14.2. Market Share Analysis, 2022
- 13.14.2.1. By Treatment
- 13.14.2.2. By End Users
- 13.15. Indonesia
- 13.15.1. Pricing Analysis
- 13.15.2. Market Share Analysis, 2022
- 13.15.2.1. By Treatment
- 13.15.2.2. By End Users
- 13.16. Australia
- 13.16.1. Pricing Analysis
- 13.16.2. Market Share Analysis, 2022
- 13.16.2.1. By Treatment
- 13.16.2.2. By End Users
- 13.17. New Zealand
- 13.17.1. Pricing Analysis
- 13.17.2. Market Share Analysis, 2022
- 13.17.2.1. By Treatment
- 13.17.2.2. By End Users
- 13.18. GCC Countries
- 13.18.1. Pricing Analysis
- 13.18.2. Market Share Analysis, 2022
- 13.18.2.1. By Treatment
- 13.18.2.2. By End Users
- 13.19. South Africa
- 13.19.1. Pricing Analysis
- 13.19.2. Market Share Analysis, 2022
- 13.19.2.1. By Treatment
- 13.19.2.2. By End Users
- 13.20. Israel
- 13.20.1. Pricing Analysis
- 13.20.2. Market Share Analysis, 2022
- 13.20.2.1. By Treatment
- 13.20.2.2. By End Users
- 14. Market Structure Analysis
- 14.1. Competition Dashboard
- 14.2. Competition Benchmarking
- 14.3. Market Share Analysis of Top Players
- 14.3.1. By Regional
- 14.3.2. By Treatment
- 14.3.3. By End Users
- 15. Competition Analysis
- 15.1. Competition Deep Dive
- 15.1.1. Alexion Pharmaceuticals
- 15.1.1.1. Overview
- 15.1.1.2. Product Portfolio
- 15.1.1.3. Profitability by Market Segments
- 15.1.1.4. Sales Footprint
- 15.1.1.5. Strategy Overview
- 15.1.1.5.1. Marketing Strategy
- 15.1.2. Argenx
- 15.1.2.1. Overview
- 15.1.2.2. Product Portfolio
- 15.1.2.3. Profitability by Market Segments
- 15.1.2.4. Sales Footprint
- 15.1.2.5. Strategy Overview
- 15.1.2.5.1. Marketing Strategy
- 15.1.3. UCB Biopharma
- 15.1.3.1. Overview
- 15.1.3.2. Product Portfolio
- 15.1.3.3. Profitability by Market Segments
- 15.1.3.4. Sales Footprint
- 15.1.3.5. Strategy Overview
- 15.1.3.5.1. Marketing Strategy
- 15.1.4. Horizon Therapeutics
- 15.1.4.1. Overview
- 15.1.4.2. Product Portfolio
- 15.1.4.3. Profitability by Market Segments
- 15.1.4.4. Sales Footprint
- 15.1.4.5. Strategy Overview
- 15.1.4.5.1. Marketing Strategy
- 15.1.5. Halozyme Therapeutics
- 15.1.5.1. Overview
- 15.1.5.2. Product Portfolio
- 15.1.5.3. Profitability by Market Segments
- 15.1.5.4. Sales Footprint
- 15.1.5.5. Strategy Overview
- 15.1.5.5.1. Marketing Strategy
- 15.1.6. F. Hoffmann-La Roche AG
- 15.1.6.1. Overview
- 15.1.6.2. Product Portfolio
- 15.1.6.3. Profitability by Market Segments
- 15.1.6.4. Sales Footprint
- 15.1.6.5. Strategy Overview
- 15.1.6.5.1. Marketing Strategy
- 15.1.7. Janssen Research & Development, LLC
- 15.1.7.1. Overview
- 15.1.7.2. Product Portfolio
- 15.1.7.3. Profitability by Market Segments
- 15.1.7.4. Sales Footprint
- 15.1.7.5. Strategy Overview
- 15.1.7.5.1. Marketing Strategy
- 15.1.8. Immunovant Sciences GmbH
- 15.1.8.1. Overview
- 15.1.8.2. Product Portfolio
- 15.1.8.3. Profitability by Market Segments
- 15.1.8.4. Sales Footprint
- 15.1.8.5. Strategy Overview
- 15.1.8.5.1. Marketing Strategy
- 15.1.9. Sanofi
- 15.1.9.1. Overview
- 15.1.9.2. Product Portfolio
- 15.1.9.3. Profitability by Market Segments
- 15.1.9.4. Sales Footprint
- 15.1.9.5. Strategy Overview
- 15.1.9.5.1. Marketing Strategy
- 15.1.10. Cartesian Therapeutics
- 15.1.10.1. Overview
- 15.1.10.2. Product Portfolio
- 15.1.10.3. Profitability by Market Segments
- 15.1.10.4. Sales Footprint
- 15.1.10.5. Strategy Overview
- 15.1.10.5.1. Marketing Strategy
- 16. Assumptions & Acronyms Used
- 17. Research Methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook